Press Releases

Press Releases

    Date Title View
    01/03/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    01/03/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    12/20/22
    Summary ToggleUPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    12/13/22
    Summary ToggleForm 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
    PDF Version
    12/12/22
    Summary ToggleRule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
    PDF Version
    12/08/22
    Summary ToggleHorizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
    PDF Version
    11/29/22
    Summary ToggleHorizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
    PDF Version
    11/16/22
    Summary ToggleHorizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
    PDF Version
    11/16/22
    Summary ToggleHorizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
    PDF Version
    11/10/22
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
    PDF Version
    Displaying 21 - 30 of 727 results